LLY

1,023.81

-1.01%↓

JNJ

240.81

+0.35%↑

ABBV

219.74

-2.09%↓

NVS

159.98

+0.64%↑

MRK

118.68

+1.04%↑

LLY

1,023.81

-1.01%↓

JNJ

240.81

+0.35%↑

ABBV

219.74

-2.09%↓

NVS

159.98

+0.64%↑

MRK

118.68

+1.04%↑

LLY

1,023.81

-1.01%↓

JNJ

240.81

+0.35%↑

ABBV

219.74

-2.09%↓

NVS

159.98

+0.64%↑

MRK

118.68

+1.04%↑

LLY

1,023.81

-1.01%↓

JNJ

240.81

+0.35%↑

ABBV

219.74

-2.09%↓

NVS

159.98

+0.64%↑

MRK

118.68

+1.04%↑

LLY

1,023.81

-1.01%↓

JNJ

240.81

+0.35%↑

ABBV

219.74

-2.09%↓

NVS

159.98

+0.64%↑

MRK

118.68

+1.04%↑

Search

Guardant Health Inc

Geschlossen

BrancheGesundheitswesen

105.05 0.23

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

103.59

Max

107.57

Schlüsselkennzahlen

By Trading Economics

Einkommen

7.2M

-93M

Verkäufe

33M

265M

Gewinnspanne

-34.965

Angestellte

1,999

EBITDA

6.6M

-82M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+21.82% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

19. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

4.7B

14B

Vorheriger Eröffnungskurs

104.82

Vorheriger Schlusskurs

105.05

Nachrichtenstimmung

By Acuity

50%

50%

149 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Guardant Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Feb. 2026, 23:26 UTC

Wichtige Markttreiber

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10. Feb. 2026, 22:31 UTC

Ergebnisse

Correction to America Movil 4Q Profit Article

10. Feb. 2026, 22:22 UTC

Ergebnisse

America Movil 4Q Profit Jumps on Lower Financial Costs

10. Feb. 2026, 23:51 UTC

Market Talk
Ergebnisse

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10. Feb. 2026, 23:42 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10. Feb. 2026, 23:40 UTC

Market Talk
Ergebnisse

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10. Feb. 2026, 23:21 UTC

Market Talk

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10. Feb. 2026, 23:21 UTC

Market Talk

Global Equities Roundup: Market Talk

10. Feb. 2026, 22:17 UTC

Market Talk

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10. Feb. 2026, 22:15 UTC

Ergebnisse

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10. Feb. 2026, 22:10 UTC

Ergebnisse

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10. Feb. 2026, 22:10 UTC

Ergebnisse

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10. Feb. 2026, 22:09 UTC

Ergebnisse

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10. Feb. 2026, 22:09 UTC

Ergebnisse

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10. Feb. 2026, 22:01 UTC

Ergebnisse

Intact Financial 4Q EPS C$5.24 >IFC.T

10. Feb. 2026, 21:54 UTC

Ergebnisse

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10. Feb. 2026, 21:53 UTC

Ergebnisse

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10. Feb. 2026, 21:51 UTC

Ergebnisse

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10. Feb. 2026, 21:51 UTC

Ergebnisse

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10. Feb. 2026, 21:51 UTC

Ergebnisse

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10. Feb. 2026, 21:51 UTC

Ergebnisse

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10. Feb. 2026, 21:51 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10. Feb. 2026, 21:50 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10. Feb. 2026, 21:50 UTC

Ergebnisse

James Hardie Industries 3Q EPS 12c >JHX

10. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. Feb. 2026, 21:50 UTC

Ergebnisse

James Hardie Industries 3Q Adj EPS 24c >JHX

10. Feb. 2026, 21:49 UTC

Ergebnisse

James Hardie Industries 3Q Sales $1.24B >JHX

10. Feb. 2026, 21:49 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10. Feb. 2026, 21:48 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10. Feb. 2026, 21:47 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Peer-Vergleich

Kursveränderung

Guardant Health Inc Prognose

Kursziel

By TipRanks

21.82% Vorteil

12-Monats-Prognose

Durchschnitt 128.33 USD  21.82%

Hoch 175 USD

Tief 105 USD

Basierend auf 19 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Guardant Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

19 ratings

18

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

38.86 / 47.41Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

149 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat